APA (7th ed.) Citation

S, I., K, M., LL, T., M, C., A, B., A, H., . . . TH, B. (2023). Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: Results of the Bosutinib Dose Optimization (BODO) Study. Annals of hematology, 102(10), 2741. https://doi.org/10.1007/s00277-023-05394-0

Chicago Style (17th ed.) Citation

S, Isfort, et al. "Step-in Dosing of Bosutinib in Pts with Chronic Phase Chronic Myeloid Leukemia (CML) After Second-generation Tyrosine Kinase Inhibitor (TKI) Therapy: Results of the Bosutinib Dose Optimization (BODO) Study." Annals of Hematology 102, no. 10 (2023): 2741. https://doi.org/10.1007/s00277-023-05394-0.

MLA (9th ed.) Citation

S, Isfort, et al. "Step-in Dosing of Bosutinib in Pts with Chronic Phase Chronic Myeloid Leukemia (CML) After Second-generation Tyrosine Kinase Inhibitor (TKI) Therapy: Results of the Bosutinib Dose Optimization (BODO) Study." Annals of Hematology, vol. 102, no. 10, 2023, p. 2741, https://doi.org/10.1007/s00277-023-05394-0.